Viropro Inc.
VPRO
Other OTC0.00
USD
- -
- -
Viropro Inc.
VPRO
(Other OTC)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Viropro Inc is an integrated developer and manufacturer of biopharmaceutical products that address unmet medical needs in an efficient and cost-effective manner. The company operates primarily through its wholly-owned subsidiary Alpha Biologics, which houses a state-of-the-art biomanufacturing facility located in Penang, Malaysia. This facility is constructed to US FDA and European EMEA current Good Manufacturing Practices (cGMP) standards and spans 5,000 square meters. Its manufacturing capabilities include biologics production such as biosimilars for pre-clinical and Phase I, II, and III clinical trials as well as early stage commercial operations. The facility features advanced equipment including a 500-liter bioreactor with capacity for expansion to commercial scale and supports processes such as mammalian cell culture and protein production. Viropro provides services encompassing the development, manufacturing, and contract manufacturing of biopharmaceutical drugs. Its product scope primarily includes biologic drugs, biosimilars, monoclonal antibodies, and recombinant proteins aimed at creating cost-effective life-saving therapeutics. The company leverages a highly trained workforce and low operational costs as key competitive advantages. In terms of recent strategic changes, Viropro has undergone a major restructuring following a strategic review completed in 2015, including write-offs associated with its Alpha Biologics facility due to management challenges and asset seizures. Since then, Viropro has focused on restructuring activities, pursuing acquisitions and partnerships to diversify its asset base and capitalize on opportunities in clinical stage drug development and revenue-generating businesses. The company remains committed to expanding its product development pipeline and contract manufacturing services to enhance shareholder value and market presence. Founded in 2000 and headquartered in San Jose, California, Viropro serves pharmaceutical and biotechnology sectors with operations principally in the United States and Malaysia. It continues to pursue growth through the advancement of its proprietary products and by offering its facility for contract biomanufacturing with an emphasis on biopharmaceutical innovation and regulatory compliance.